0.80
+0.0239(+3.10%)
Currency In USD
| Previous Close | 0.77 |
| Open | 0.77 |
| Day High | 0.81 |
| Day Low | 0.76 |
| 52-Week High | 8.3 |
| 52-Week Low | 0.58 |
| Volume | 179,941 |
| Average Volume | 1.62M |
| Market Cap | 20.63M |
| PE | -0.77 |
| EPS | -1.04 |
| Moving Average 50 Days | 1.03 |
| Moving Average 200 Days | 1.48 |
| Change | 0.02 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $8.14 as of March 13, 2025 at a share price of $0.796. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $8.06 as of March 13, 2025 at a share price of $0.796.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
GlobeNewswire Inc.
Mar 10, 2025 12:00 PM GMT
SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising preclinica
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
GlobeNewswire Inc.
Feb 24, 2025 1:00 PM GMT
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that Northwestern Uni
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
GlobeNewswire Inc.
Jan 29, 2025 1:00 PM GMT
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a w